Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate AHRQ appropriations

Executive Summary

Senate fiscal 2006 HHS appropriations bill budgets $20 mil. for the Agency for Healthcare Research & Quality to perform comparative effectiveness research. The bill allocates $5 mil. more than the President's budget request and $5 mil. more than funding provided in the House HHS appropriations bill that passed in June. The research, which was mandated by the Medicare Modernization Act, was funded at $15 mil. in the fiscal 2005 omnibus appropriation bill (1"The Pink Sheet" Dec. 20, 2004, p. 11)...

You may also be interested in...



AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”

Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15

Cosmetic And Personal Care Trademark Review: 9 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel